Prädisposition, frühe Stadien und Phänotypen des Typ-1-Diabetes

Schlüsselwörter

Typ-1-Diabetes - Prädisposition - Stadien - Phänotyp

Keywords

type 1 diabetes - predisposition - stages - phenotype

• Literatur

• 1 Achenbach P, Bonifacio E, Williams AJ et al. Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia 2008; 51: 488-492
• 2 Achenbach P, Hummel M, Thumer L et al. Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. Diabetologia 2013; 56: 1615-1622
• 3 Achenbach P, Koczwara K, Knopff A et al. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004; 114: 589-597
• 4 Achenbach P, Lampasona V, Landherr U et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009; 52: 1881-1888
• 5 Achenbach P, Warncke K, Reiter J et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53: 384-392
• 6 Aly TA, Ide A, Jahromi MM et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A 2006; 103: 14074-14079
• 7 Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229
• 8 Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010; 95: 25-33
• 9 Bonifacio E, Hummel M, Walter M et al. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004; 27: 2695-2700
• 10 Bonifacio E, Krumsiek J, Winkler C et al. A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion. Acta Diabetol 2013; PMID: 24249616
• 11 Bonifacio E, Warncke K, Winkler C et al. Cesarean section and interferon-induced helicase gene polymorphisms combine to increase childhood type 1 diabetes risk. Diabetes 2011; 60: 3300-3306
• 12 De Grijse J, Asanghanwa M, Nouthe B et al. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010; 53: 517-524
• 13 Ehehalt S, Dietz K, Willasch AM et al. Epidemiological perspectives on type 1 diabetes in childhood and adolescence in germany: 20 years of the Baden-Wurttemberg Diabetes Incidence Registry (DIARY). Diabetes Care 2010; 33: 338-340
• 14 Elding Larsson H, Vehik K, Bell R et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 2011; 34: 2347-2352
• 15 Ferrannini E, Mari A, Nofrate V et al. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010; 59: 679-685
• 16 Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167
• 17 Gillespie KM, Gale EA, Bingley PJ. High familial risk and genetic susceptibility in early onset childhood diabetes. Diabetes 2002; 51: 210-214
• 18 Hummel M, Bonifacio E, Schmid S et al. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med 2004; 140: 882-886
• 19 Karvonen M, Viik-Kajander M, Moltchanova E et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23: 1516-1526
• 20 Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med 2012; 2: a007690
• 21 Krischer JP. Type 1 Diabetes TrialNet Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 2013; 56: 1919-1924
• 22 Mayr A, Schlosser M, Grober N et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007; 56: 1527-1533
• 23 Neu A, Hofer SE, Karges B et al. Ketoacidosis at diabetes onset is still frequent in children and adolescents: a multicenter analysis of 14,664 patients from 106 institutions. Diabetes Care 2009; 32: 1647-1648
• 24 Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32: 2269-2274
• 25 Parikka V, Nanto-Salonen K, Saarinen M et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012; 55: 1926-1936
• 26 Patterson CC, Dahlquist GG, Gyurus E et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373: 2027-2033
• 27 Redondo MJ, Eisenbarth GS. Genetic control of autoimmunity in Type I diabetes and associated disorders. Diabetologia 2002; 45: 605-622
• 28 Redondo MJ, Yu L, Hawa M et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 2001; 44: 354-362
• 29 Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial – Type 1. Diabetes Care 2005; 28: 1068-1076
• 30 Sosenko JM, Palmer JP, Greenbaum CJ et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006; 29: 643-649
• 31 Sosenko JM, Palmer JP, Rafkin-Mervis L et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008; 31: 2188-2192
• 32 Steck AK, Armstrong TK, Babu SR et al. Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. Diabetes 2011; 60: 1045-1049
• 33 Todd JA. Etiology of type 1 diabetes. Immunity 2010; 32: 457-467
• 34 Triolo TM, Chase HP, Barker JM et al. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care 2009; 32: 769-773
• 35 Winkler C, Lauber C, Adler K et al. An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes 2011; 60: 685-690
• 36 Winkler C, Schober E, Ziegler AG et al. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes 2012; 13: 308-313
• 37 Ziegler AG, Bonifacio E. BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012; 55: 1937-1943
• 38 Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010; 32: 468-478
• 39 Ziegler AG, Pflueger M, Winkler C et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun 2011; 37: 3-7
• 40 Ziegler AG, Rewers M, Simell O et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479